Outcome at 2 years after HSCT by cytogenetic classification
| . | Frequency, N . | OS% (95% CI) . | EFS% (95% CI) . | CIR% (95% CI) . | NRM% (95% CI) . |
|---|---|---|---|---|---|
| All patients | |||||
| ELN intermediate 2 | 70 | 71 (61-82) | 64 (53-76) | 22 (12-32) | 14 (5-22) |
| ELN adverse | 166 | 42 (34-50) | 37 (30-45) | 40 (32-48) | 23 (16-29) |
| P* | < .001 | < .001 | .007 | .1 | |
| Intermediate risk 2 | |||||
| Trisomy 8 alone | 31 | 67 (51-84) | 63 (46-81) | 20 (5-34) | 17 (3-31) |
| t(9;11)(p22;q23) | 8 | 70 (34-100) | 50 (15-85) | 50 (12-88) | 0 (0-0) |
| Other | 31 | 75 (59-91) | 69 (53-86) | 17 (3-30) | 14 (1-27) |
| P* | .9 | .6 | .1 | .5 | |
| AML with recurrent adverse abnormalities (WHO) | |||||
| Abnl (3) | 9 | 44 (12-77) | 33 (3-64) | 56 (19-92) | 11 (0-33) |
| t(6;9) | 14 | 71 (46-95) | 63 (38-89) | 15 (0-35) | 21 (0-44) |
| t(v;11)(v;q23) | 22 | 51 (28-73) | 41 (20-63) | 44 (21-66) | 15 (0-32) |
| P* | .3 | .2 | .05 | .8 | |
| ELN adverse by CK | |||||
| CK− | 69 | 53 (41-65) | 48 (36-60) | 30 (19-41) | 22 (12-33) |
| CK+ | 97 | 35 (24-45) | 29 (19-39) | 48 (37-58) | 23 (14-32) |
| P* | .03 | .03 | .03 | 1 | |
| Subclassification of CK | |||||
| 3-4 abnl | 35 | 62 (45-78) | 55 (37-72) | 28 (12-44) | 18 (5-31) |
| 5-9 abnl | 38 | 18 (4-33) | 12 (0-26) | 59 (39-79) | 29 (12-45) |
| ≥ 10 abnl | 24 | 21 (5-37) | 17 (2-32) | 62 (42-83) | 21 (4-38) |
| P* | < .001 | < .001 | .002 | .9 | |
| ELN adverse by MK | |||||
| MK− | 101 | 51 (40-61) | 46 (36-57) | 30 (21-39) | 24 (15-33) |
| MK+ | 65 | 30 (18-41) | 24 (14-35) | 55 (42-67) | 21 (10-31) |
| P* | .002 | .002 | .001 | .6 | |
| Hierarchical lesion-specific | |||||
| No abnl(17p) and no −5/5q− | 95 | 53 (43-64) | 49 (39-59) | 31 (22-41) | 20 (11-28) |
| No abnl(17p), but −5/5q− | 41 | 30 (15-45) | 29 (15-44) | 51 (35-67) | 20 (7-33) |
| abnl(17p) | 30 | 25 (8-41) | 11 (0-25) | 53 (32-73) | 36 (17-56) |
| P* | < .001 | < .001 | .05 | .1 |
| . | Frequency, N . | OS% (95% CI) . | EFS% (95% CI) . | CIR% (95% CI) . | NRM% (95% CI) . |
|---|---|---|---|---|---|
| All patients | |||||
| ELN intermediate 2 | 70 | 71 (61-82) | 64 (53-76) | 22 (12-32) | 14 (5-22) |
| ELN adverse | 166 | 42 (34-50) | 37 (30-45) | 40 (32-48) | 23 (16-29) |
| P* | < .001 | < .001 | .007 | .1 | |
| Intermediate risk 2 | |||||
| Trisomy 8 alone | 31 | 67 (51-84) | 63 (46-81) | 20 (5-34) | 17 (3-31) |
| t(9;11)(p22;q23) | 8 | 70 (34-100) | 50 (15-85) | 50 (12-88) | 0 (0-0) |
| Other | 31 | 75 (59-91) | 69 (53-86) | 17 (3-30) | 14 (1-27) |
| P* | .9 | .6 | .1 | .5 | |
| AML with recurrent adverse abnormalities (WHO) | |||||
| Abnl (3) | 9 | 44 (12-77) | 33 (3-64) | 56 (19-92) | 11 (0-33) |
| t(6;9) | 14 | 71 (46-95) | 63 (38-89) | 15 (0-35) | 21 (0-44) |
| t(v;11)(v;q23) | 22 | 51 (28-73) | 41 (20-63) | 44 (21-66) | 15 (0-32) |
| P* | .3 | .2 | .05 | .8 | |
| ELN adverse by CK | |||||
| CK− | 69 | 53 (41-65) | 48 (36-60) | 30 (19-41) | 22 (12-33) |
| CK+ | 97 | 35 (24-45) | 29 (19-39) | 48 (37-58) | 23 (14-32) |
| P* | .03 | .03 | .03 | 1 | |
| Subclassification of CK | |||||
| 3-4 abnl | 35 | 62 (45-78) | 55 (37-72) | 28 (12-44) | 18 (5-31) |
| 5-9 abnl | 38 | 18 (4-33) | 12 (0-26) | 59 (39-79) | 29 (12-45) |
| ≥ 10 abnl | 24 | 21 (5-37) | 17 (2-32) | 62 (42-83) | 21 (4-38) |
| P* | < .001 | < .001 | .002 | .9 | |
| ELN adverse by MK | |||||
| MK− | 101 | 51 (40-61) | 46 (36-57) | 30 (21-39) | 24 (15-33) |
| MK+ | 65 | 30 (18-41) | 24 (14-35) | 55 (42-67) | 21 (10-31) |
| P* | .002 | .002 | .001 | .6 | |
| Hierarchical lesion-specific | |||||
| No abnl(17p) and no −5/5q− | 95 | 53 (43-64) | 49 (39-59) | 31 (22-41) | 20 (11-28) |
| No abnl(17p), but −5/5q− | 41 | 30 (15-45) | 29 (15-44) | 51 (35-67) | 20 (7-33) |
| abnl(17p) | 30 | 25 (8-41) | 11 (0-25) | 53 (32-73) | 36 (17-56) |
| P* | < .001 | < .001 | .05 | .1 |
HSCT indicates hematopoietic stem cell transplantation; OS, overall survival; CI, confidence interval; EFS, event-free survival; CIR, cumulative incidence of relapse; NRM, nonrelapse mortality; ELN, European LeukemiaNet; AML, acute myeloid leukemia; and abnl, abnormality.
abnl(3), inv(3)(q21q26.2) or t (3;3)(q21;q26.2); t (v;11)(v;q23) indicate balanced translocations other than involving the MLLT3 gene on 9p22. Abnl(17p) indicates abnormality of chromosome 17. CK indicates complex karyotype defined by ≥ 3 independent clonal abnormalities. MK indicates monosomal karyotype defined by the presence of 2 or more distinct autosomal chromosome monosomies in the karyotype or a single autosomal monosomy in the presence of 1 or more structural chromosomal abnormalities.
P values were calculated using the Gray test for CIR and NRM and the log-rank test for OS and EFS.